[GRAPHIC OMITTED][GRAPHIC OMITTED]

Media/Investors contact:
Jonathan Fassberg
The Trout Group
(212) 477-9007 x16

    CYTOGEN TO RAISE $13.3 MILLION THROUGH SALE OF COMMON STOCK AND WARRANTS

PRINCETON, NEW JERSEY - DECEMBER 13, 2005 - Cytogen Corporation (NASDAQ:CYTO), a
product-driven  biopharmaceutical  company,  announced today that it has entered
into definitive purchase agreements with certain institutional investors for the
sale of 3,729,556  shares of its common  stock and 932,389  warrants to purchase
shares  of its  common  stock  at a unit  price  of $3.56  per  unit  through  a
registered  direct offering.  The warrants have a five-year term and an exercise
price of $4.25 per share.  The transaction is expected to provide gross proceeds
of approximately $13.3 million to Cytogen before deducting costs associated with
the  offering,  and  will be used  primarily  for  general  corporate  purposes,
including the selling,  marketing and clinical development of Cytogen's products
and product  candidates.  The parties expect to close the transaction as soon as
possible.

The  shares of common  stock and the  shares  of  common  stock  underlying  the
warrants offered by Cytogen in this transaction will be registered upon issuance
under the Company's existing shelf registration statement on Form S-3, which was
declared  effective by the  Securities  and Exchange  Commission on November 14,
2004. Rodman & Renshaw acted as placement agent in this transaction.

This press release shall not constitute an offer to sell or the  solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
jurisdiction  in which such offer,  solicitation or sale would be unlawful prior
to registration or qualification  under the securities laws of any such state or
jurisdiction.

ABOUT CYTOGEN CORPORATION

Founded in 1980,  Cytogen  Corporation of Princeton,  NJ is a  biopharmaceutical
company  that  acquires,   develops  and  commercializes   innovative  molecules
targeting  the  sites  and  stages of  cancer  progression.  Cytogen's  marketed
products  include  QUADRAMET(R)   (samarium  Sm-153  lexidronam  injection)  and
PROSTASCINT(R)  (capromab  pendetide)  kit for the  preparation of Indium In-111
capromab  pendetide  in the United  States.  Cytogen also has  exclusive  United
States marketing rights to COMBIDEX(R)  (ferumoxtran-10)  for all  applications,
and the exclusive right to market and sell  ferumoxytol  (previously  Code 7228)
for oncology  applications in the United States.  Cytogen's development pipeline
consists of therapeutics targeting prostate- specific membrane antigen (PSMA), a
protein  highly  expressed  on the  surface  of  prostate  cancer  cells and the
neovasculature of solid tumors.  Full prescribing  information for the Company's
products is available at  www.cytogen.com or by calling  800-833-3533.  For more
information, please visit the Company's website at www.cytogen.com, which is not
part of this press release.


This press release  contains  certain  "forward-looking"  statements  within the
meaning of the Private Securities  Litigation Reform Act of 1995 and Section 21E
of the Securities Exchange Act of 1934, as amended.  All statements,  other than
statements of historical facts, included in this press release regarding,  among
other things,  our use of proceeds from this  registered  direct  offering,  are
forward-looking  statements. Such forward-looking statements involve a number of
risks  and  uncertainties  and  investors  are  cautioned  not to put any  undue
reliance  on any  forward-looking  statement.  There are a number  of  important
factors  that could  cause  Cytogen's  results to differ  materially  from those
indicated by such forward-looking statements. In particular,  Cytogen's business
is subject to a number of significant risks, which include,  but are not limited
to: the risk that the closing  conditions will not be met; the risk of obtaining
the necessary  regulatory  approvals;  the risk of whether  products result from
development  activities;  the  risk  of  shifts  in the  regulatory  environment
affecting sales of Cytogen's  products such as third-party  payor  reimbursement
issues; the risk associated with Cytogen's





dependence on its partners for development of certain projects, as well as other
factors  expressed  from time to time in  Cytogen's  periodic  filings  with the
Securities and Exchange  Commission (the "SEC"). As a result, this press release
should be read in conjunction with Cytogen's  periodic filings with the SEC. The
forward-looking statements contained herein are made only as of the date of this
press  release,  and Cytogen  undertakes no  obligation to publicly  update such
forward-looking statements to reflect subsequent events or circumstances.

                                       ###